Guggenheim maintains Travere Therapeutics at Buy, lowers price target to $78 from $89
Guggenheim kept its Buy rating on Travere Therapeutics but reduced its price target from $89 to $78, a 12.4% decrease. The new target suggests a 57.9% upside from the Nov 3 close of $49.41, according to the firm.
How this was made
The 30-second read
Why it matters
The downgrade in price target signals reduced near‑term upside, likely prompting traders to trim positions.
Market read
Analyst target cuts are a primary catalyst for price movement in small‑cap stocks.
What to watch
Potential pipeline milestones not reflected in the target change.
Background
Guggenheim Research maintains a Buy rating on Travere Therapeutics while adjusting its valuation.
Market effects
May weigh on other small‑cap biotech stocks as analysts tighten expectations.
Limited to US biotech sector.
Minimal beyond niche biotech investors.
Counterpoint
Target cut could be over‑reactive; upcoming trial data may still drive upside.
Key entities
- CompanyTravere Therapeutics
US‑listed biotech firm (NASDAQ: TRVR).
- AnalystGuggenheim
Equity research firm issuing the target change.
